title: Sphingosine-1-phosphate acting via the S1P₁ receptor is a downstream signaling pathway in ceramide-induced hyperalgesia.
abstract: Ceramide is a potent pro-inflammatory sphingolipid recently shown to exert potent hyperalgesic responses in rats. Once generated, ceramide is converted by sphingosine kinase (SphK) 1 and/or 2 to one of its active metabolite sphingosine-1-phosphate (S1P), which in turn signals through G-protein coupled S1P receptors. The objectives of this paper were to define whether ceramide-induced hyperalgesia is driven by S1P. Our results show that intraplantar injection of ceramide in rats led to a time-dependent development of thermal hyperalgesia that was associated with an increase in tumor necrosis factor-α (TNF-α) in paw tissues. The development of hyperalgesia was significantly attenuated by a soluble TNF receptor I. TNF-α is known to activate SphK1, thus S1P production, and our results demonstrate that, the development of hyperalgesia was attenuated in a dose-dependent fashion by a well characterized inhibitor of SphK1 and SphK2 (SK-I) and by a murine monoclonal anti-S1P antibody (LT1002). LT1017, the isotype-matched control monoclonal antibody for LT1002, had no effect. Our results further demonstrate that S1P contributes to the development of hyperalgesia via the S1P receptor 1 subtype (S1PR(1)), since responses were blocked by a well characterized S1PR(1) antagonist, W146, but not by its inactive enantiomer, W140. Collectively, these results provide mechanistic evidence implicating the S1P-to-S1PR(1) pathway as a downstream signaling pathway in ceramide-induced hyperalgesia. Targeting S1P may be a novel therapeutic approach in pain management.
authors: Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, 1402 South Grand Blvd, St. Louis, MO 63104, USA.
authors: Tim
authors: T
authors: Doyle
authors: Zhoumou
authors: Z
authors: Chen
authors: Lina M
authors: LM
authors: Obeid
authors: Daniela
authors: D
authors: Salvemini
references: Naunyn Schmiedebergs Arch Pharmacol. 2009 Oct;380(4):303-9
references: 19636535
references: Sheng Li Xue Bao. 2008 Oct 25;60(5):603-4
references: 18958367
references: J Physiol. 2006 Aug 15;575(Pt 1):101-13
references: 16740613
references: Nat Chem Biol. 2006 Aug;2(8):434-41
references: 16829954
references: Nat Rev Drug Discov. 2010 Nov;9(11):883-97
references: 21031003
references: Immunol Rev. 2008 Jun;223:221-35
references: 18613839
references: Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
references: 18216770
references: J Physiol. 2002 Oct 15;544(2):385-402
references: 12381813
references: Pain. 1988 Jan;32(1):77-88
references: 3340425
references: Eur J Neurosci. 2004 Dec;20(11):2896-902
references: 15579143
references: J Lipid Res. 2009 Nov;50(11):2245-57
references: 19509417
references: J Neurosci. 2003 Apr 1;23(7):3028-38
references: 12684490
references: J Biol Chem. 2005 Dec 30;280(52):43030-8
references: 16243846
references: J Neurosci. 2010 Nov 17;30(46):15400-8
references: 21084596
references: Biochim Biophys Acta. 2004 Jun 1;1682(1-3):48-55
references: 15158755
references: Br J Pharmacol. 2011 Mar;162(6):1225-38
references: 21091645
references: Biochim Biophys Acta. 2006 Dec;1758(12):1957-77
references: 17049336
references: Pain. 2011 Mar;152(3):643-648
references: 21239112
references: Neurochem Res. 2008 Oct;33(10):1970-8
references: 18427980
references: Neuroscience. 2008 Nov 19;157(2):414-23
references: 18838115
references: Cancer Res. 2003 Sep 15;63(18):5962-9
references: 14522923
references: Biochimie. 2010 Jun;92(6):707-15
references: 20156522
references: J Neurophysiol. 2006 Sep;96(3):1042-52
references: 16723416
references: Pharmacol Rev. 2008 Jun;60(2):181-95
references: 18552276
references: FASEB J. 2011 Aug;25(8):2782-91
references: 21551240
references: J Pharmacol Exp Ther. 2009 Apr;329(1):64-75
references: 19033555
references: Neurosci Lett. 2009 Sep 29;463(1):49-53
references: 19631718
references: Biochim Biophys Acta. 2008 Jan;1784(1):66-75
references: 17913601
references: J Trauma. 2004 Nov;57(5):955-60
references: 15580017
references: J Neurophysiol. 2010 Nov;104(5):2741-8
references: 20844107
references: PLoS One. 2011 Feb 17;6(2):e17268
references: 21359147
references: J Orofac Pain. 2009 Spring;23(2):167-73
references: 19492541
references: J Pharmacol Exp Ther. 2004 Jun;309(3):869-78
references: 14988418